HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

Benzinga · 2d ago
HC Wainwright & Co. analyst Brandon Folkes reiterates Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $29 price target.